Filtered By:
Specialty: Cardiology
Drug: Metformin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 31 results found since Jan 2013.
Metformin Directly Binds to MMP-9 to Improve Plaque Stability
J Cardiovasc Dev Dis. 2023 Jan 30;10(2):54. doi: 10.3390/jcdd10020054.ABSTRACTVulnerable atherosclerotic plaque rupture is the principal mechanism that accounts for myocardial infarction and stroke. High matrix metalloproteinase-9 (MMP-9) expression and activity have been proven to lead to plaque instability. Metformin, a first-line treatment for type 2 diabetes, is beneficial to plaque vulnerability. However, the mechanism underlying its anti-atherogenic effect remains unclear. Molecular docking and surface plasmon resonance experiments showed that metformin directly interacts with MMP-9, and incubated MMP-9 overexpressin...
Source: Atherosclerosis - February 24, 2023 Category: Cardiology Authors: Xianda Chen Shuaixing Wang Wenli Xu Mingming Zhao Youyi Zhang Han Xiao Source Type: research
Why Are Cardiologists Not Prescribing the New Diabetes Medications?
Randomized clinical trials and guidelines from multiple societies have established significant cardiovascular (CV) outcome benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D). Among patients with T2D, those with known CV disease and those at high risk who are receiving metformin have lower risks of death, myocardial infarction, and stroke if they are treated with GLP-1RAs, and those treated with SGLT2is have reduced risks of hospital admission for heart failure, CV mortality, and all-cause mortality.
Source: The American Journal of Cardiology - December 14, 2022 Category: Cardiology Authors: Lloyd W. Klein Source Type: research
SGLT-2 inhibitors as First-Line Therapy in Type 2 Diabetes? SGLT-2 inhibitors as First-Line Therapy in Type 2 Diabetes?
Real-world study finds heart failure hospitalization reduction compared to metformin but not MI, stroke, or overall mortality, and greater genital infection risk.Medscape Medical News
Source: Medscape Cardiology Headlines - May 23, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
SGLT2 Inhibitors a Better First Drug in Type 2 Diabetes Than Metformin?
(MedPage Today) -- Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed.
The combined 12-month risk for myocardial infarction (MI), stroke, and death was similar...
Source: MedPage Today Cardiovascular - May 23, 2022 Category: Cardiology Source Type: news
Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease
Fertil Steril. 2022 May;117(5):924-935. doi: 10.1016/j.fertnstert.2022.03.009.ABSTRACTPolycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age and is hallmarked by hyperandrogenism, oligo-ovulation, and polycystic ovarian morphology. Polycystic ovary syndrome, particularly the hyperandrogenism phenotype, is associated with several cardiometabolic abnormalities, including obesity, dyslipidemia, elevated blood pressure, and prediabetes or type 2 diabetes. Many, but not all, studies have suggested that PCOS is associated with increased risk of cardiovascular disease (CVD), includi...
Source: Atherosclerosis - May 5, 2022 Category: Cardiology Authors: Carolyn Guan Salman Zahid Anum S Minhas Pamela Ouyang Arthur Vaught Valerie L Baker Erin D Michos Source Type: research
Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association
Circulation. 2021 Mar 29:CIR0000000000000961. doi: 10.1161/CIR.0000000000000961. Online ahead of print.ABSTRACTThis statement summarizes evidence that adverse pregnancy outcomes (APOs) such as hypertensive disorders of pregnancy, preterm delivery, gestational diabetes, small-for-gestational-age delivery, placental abruption, and pregnancy loss increase a woman's risk of developing cardiovascular disease (CVD) risk factors and of developing subsequent CVD (including fatal and nonfatal coronary heart disease, stroke, peripheral vascular disease, and heart failure). This statement highlights the importance of recognizing APOs...
Source: Circulation - March 29, 2021 Category: Cardiology Authors: Nisha I Parikh Juan M Gonzalez Cheryl A M Anderson Suzanne E Judd Kathryn M Rexrode Mark A Hlatky Erica P Gunderson Jennifer J Stuart Dhananjay Vaidya American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombos Source Type: research
Use of sodium –glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
ConclusionIn a contemporary HF cohort with T2DM, SGLT2i use increased over time, was more common with specialist care, younger age, ischaemic heart disease, and preserved renal function, and was associated with lower mortality and morbidity.
Source: European Journal of Heart Failure - March 3, 2021 Category: Cardiology Authors: Peter M. Becher,
Benedikt Schrage,
Giulia Ferrannini,
Lina Benson,
Javed Butler,
Juan Jesus Carrero,
Francesco Cosentino,
Ulf Dahlstr öm,
Linda Mellbin,
Giuseppe M.C. Rosano,
Gianfranco Sinagra,
Davide Stolfo,
Lars H. Lund,
Gianluigi Savares Tags: Research Article Source Type: research
Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient
Metformin has been shown to have various cardiovascular benefits beyond its antihyperglycemic effects, including a reduction in stroke, heart failure, myocardial infarction, cardiovascular death, and all-cause...
Source: Cardiovascular Diabetology - November 24, 2020 Category: Cardiology Authors: Teerapat Nantsupawat, Wanwarang Wongcharoen, Siriporn C. Chattipakorn and Nipon Chattipakorn Tags: Review Source Type: research
Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis.
CONCLUSIONS: Both GLP-1 agonists and SGLT-2 inhibitors showed comparable cardiovascular outcomes in patients with type 2 diabetes. However, the SGLT-2 inhibitors were associated with more pronounced reduction of hospitalization for HF and lower risk of treatment discontinuation than GLP-1 agonists.
PMID: 33140391 [PubMed - as supplied by publisher]
Source: Cardiology Journal - November 3, 2020 Category: Cardiology Authors: Lee YM, Lee SH, Kim TH, Park EJ, Park YA, Jang JS Tags: Cardiol J Source Type: research
Meta-analysis Assessing the Effect of Sodium-glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) has evolved as a pandemic of the 21st century, while cardiovascular disease (CVD) affects almost one third of patients and represents the cause of death in more than half cases, with coronary artery disease, heart failure (HF) and stroke being the main contributors.1 Hallmark cardiovascular outcome trials published during the last five years have established a novel class of antidiabetics, namely sodium-glucose co-transporter-2 (SGLT-2) inhibitors as a primary treatment option in patients with HF, atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD), along with the ...
Source: The American Journal of Cardiology - August 6, 2020 Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, Maria-Styliani Kalogirou, Michael Doumas Source Type: research
Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
Conclusions: EXSCEL-observed HRs for MACE and ACM remained robust after right censoring or application of literature-derived risk reductions, but the exenatide versus placebo MACE effect size and statistical significance were increased by IPTW. Effects of open-label drop-in cardioprotective medications need to be considered carefully when designing, conducting, and analyzing cardiovascular outcome trials of glucose-lowering agents under the premise of glycemic equipoise. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01144338.
PMID: 32098501 [PubMed - as supplied by publisher]
Source: Circulation - February 25, 2020 Category: Cardiology Authors: Bethel MA, Stevens SR, Buse JB, Choi J, Gustavson SM, Iqbal N, Lokhnygina Y, Mentz RJ, Patel RA, Öhman P, Schernthaner G, Lecube A, Hernandez AF, Holman RR Tags: Circulation Source Type: research
A randomised, double ‐blind, placebo‐controlled trial of metformin on myocardial efficiency in insulin‐resistant chronic heart failure patients without diabetes
ConclusionMetformin treatment in non ‐diabetic HFrEF patients improved myocardial efficiency by reducing myocardial oxygen consumption. Measurement of circulating metformin levels differentiated responders from non‐responders. These energy‐sparing effects of metformin encourage further large‐scale investigations in heart failur e patients without diabetes.
Source: European Journal of Heart Failure - December 20, 2019 Category: Cardiology Authors: Anders Hostrup Larsen,
Niels Jessen,
Helene N ørrelund,
Lars Poulsen Tolbod,
Hendrik Johannes Harms,
Søren Feddersen,
Flemming Nielsen,
Kim Brøsen,
Nils Henrik Hansson,
Jørgen Frøkiær,
Steen Hvitfeldt Poulsen,
Jens Sörensen,
Henrik Wigg Tags: Research Article Source Type: research
